Chemomab Therapeutics Appoints New Director, Realigns Board Committees Amidst Two Resignations
Summary
Chemomab Therapeutics announced the appointment of Gwen Melincoff as a new independent director and chair of the nominating committee, following the simultaneous resignations of two other directors.
Key Events
-
New Independent Director Appointed
Gwen Melincoff, a seasoned biopharmaceutical professional with extensive board experience, was appointed as a Class I Director and Chair of the Nominating and Governance Committee, effective June 1, 2026.
-
Two Directors Resign
Claude Nicaise and Jill Quigley simultaneously resigned from the Board and Audit Committee, effective May 29, 2026. The company stated their resignations were not due to any disagreements.
-
Audit Committee Reconfigured
Neil Cohen and Dr. Nissim Darvish were appointed to the Audit Committee, effective June 1, 2026, with Mr. Cohen taking the chair role.
Analysis
This filing details significant changes to Chemomab Therapeutics' Board of Directors. While two directors resigned, the company appointed Gwen Melincoff, an experienced biopharmaceutical professional, to the board and as chair of the nominating committee. These changes occur in the context of the company's recent 'going concern' disclosure and proposed share dilution, making board stability and strong governance particularly important for investor confidence.
At the time of this filing, CMMB was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $1.35 to $5.52. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.